MedTrace Logo

Retrospective Study With Patients Treated With STALIF® C or M and Ti or FLX Implants for 1 and 2 Levels

NCT05610397 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2023-01-12

No results posted yet for this study

Summary

This is a Retrospective, Observational Multi-Center study, utilizing patients diagnosed with up to a Grade1 spondylolisthesis or retrolisthesis or symptomatic degenerative disc disease and treated with STALIF® C, or M, Ti and/or FLX implants at one or two levels.

Conditions

  • Degenerative Disc Disease
  • Grade 1 Spondylolisthesis
  • Retrolisthesis
  • Symptomatic Cervical Disc Disease

Interventions

DEVICE

STALIF®

STALIF® C, or M, Ti or FLX

Sponsors & Collaborators

  • Centinel Spine

    lead INDUSTRY

Principal Investigators

  • Bernd Illerhaus, MD · Orthopädisch-Neurochirurgisches Zentrum

Eligibility

Min Age
21 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-04-24
Primary Completion
2024-04-30
Completion
2024-09-30
FDA Device
Yes

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05610397 on ClinicalTrials.gov